Prosecutors Target Russian Clinic Testing British Firm's Mmr Vaccine
Russian prosecutors have opened a criminal investigation into a clinic after unsubstantiated allegations that a vaccine made by the British drugs company GlaxoSmithKline has had disturbing side effects in a clinical trial. Prosecutors in Volgograd are investigating a clinic that tested the chickenpox, measles, mumps and rubella vaccine on 100 babies between the ages of one and two.
Prosecutors say at least one of the children developed alarming symptoms after receiving the vaccine. A regional court last week halted the trial, by the city's Independent clinical hospital, amid complaints from parents that they had not been fully informed they were taking part in an experiment.
It follows complaints by the family of Vika Gerasinka, who was given the GlaxoSmithKline vaccine in November 2005. Her family claim that before receiving the shots she was developing normally, and was able to say 10 words. Afterwards, however, they allege that she became fretful and developed problems.
"Since getting her shots, Vika and I have been to the hospital on several occasions. She has frequently been sick," her grandmother, Lyubov Gerasinka, said. Vika, now two and a half, had serious speech and psychological problems, she added.
Yesterday GlaxoSmithKline, the world's second biggest pharmaceutical company, said the vaccines in the trial were entirely safe and had been extensively tested.
The clinical trial involved 5,700 adults and children in 10 European countries including Russia, a spokeswoman said. All three vaccines - Varilrix, against chickenpox; Priorix-Tetra, a combined MMR and chickenpox vaccine; and Priorix, a new MMR vaccine - had been approved by European and Russian regulators.
"GlaxoSmithKline is extremely concerned about the unsubstantiated and untrue allegations circulating relating to clinical trials in Russia," Michael Crow, the firm's Russia vice-president, told the Guardian. He said an internal audit had found "no signs of misconduct" by the private Volgograd clinic. There was also no evidence to link Vika Gerasinka's problems with the MMR vaccine, he added.
The clinic received $50,000 (£25,500) from the British drugs company to carry out the trial, prosecutors say. The Rossiskaya Gazeta newspaper cited local doctors as saying one of the problems with the trial may have been the fact that so few babies were healthy in the first place.
Yesterday a spokeswoman for the Volgo-grad prosecutor's office said the criminal case was against the clinic and not GlaxoSmithKline. "GlaxoSmithKline contracted the clinic, so the clinic was responsible," Lidia Sergeyeva said. She made clear, though, that future action against the drug maker was not impossible.
Prosecutors say at least one of the children developed alarming symptoms after receiving the vaccine. A regional court last week halted the trial, by the city's Independent clinical hospital, amid complaints from parents that they had not been fully informed they were taking part in an experiment.
It follows complaints by the family of Vika Gerasinka, who was given the GlaxoSmithKline vaccine in November 2005. Her family claim that before receiving the shots she was developing normally, and was able to say 10 words. Afterwards, however, they allege that she became fretful and developed problems.
"Since getting her shots, Vika and I have been to the hospital on several occasions. She has frequently been sick," her grandmother, Lyubov Gerasinka, said. Vika, now two and a half, had serious speech and psychological problems, she added.
Yesterday GlaxoSmithKline, the world's second biggest pharmaceutical company, said the vaccines in the trial were entirely safe and had been extensively tested.
The clinical trial involved 5,700 adults and children in 10 European countries including Russia, a spokeswoman said. All three vaccines - Varilrix, against chickenpox; Priorix-Tetra, a combined MMR and chickenpox vaccine; and Priorix, a new MMR vaccine - had been approved by European and Russian regulators.
"GlaxoSmithKline is extremely concerned about the unsubstantiated and untrue allegations circulating relating to clinical trials in Russia," Michael Crow, the firm's Russia vice-president, told the Guardian. He said an internal audit had found "no signs of misconduct" by the private Volgograd clinic. There was also no evidence to link Vika Gerasinka's problems with the MMR vaccine, he added.
The clinic received $50,000 (£25,500) from the British drugs company to carry out the trial, prosecutors say. The Rossiskaya Gazeta newspaper cited local doctors as saying one of the problems with the trial may have been the fact that so few babies were healthy in the first place.
Yesterday a spokeswoman for the Volgo-grad prosecutor's office said the criminal case was against the clinic and not GlaxoSmithKline. "GlaxoSmithKline contracted the clinic, so the clinic was responsible," Lidia Sergeyeva said. She made clear, though, that future action against the drug maker was not impossible.

Use the feedback form below to submit your comments.

Use the form below to email this article to your friends.

- Russia Tells British Council to Shut Offices
- Sect Members Wait in Russian Cave for World to End
- Bus Bomb Kills Eight in Russian City of Tolyatti
- Hand of John the Baptist in Russia
- Medvedev Warns Against Nato Admission for Russian Neighbours
- Russian Head of British Council Group Arrested
- Russia Arrests Two Men in British Council Spying Row
- Anglo-Russian Relations
- Russia's Priests Told to Carry Guns to Foil Armed Icon-raiders
- Climate Change May Spark Conflict With Russia, Eu Told
- EU Concerned As Russia Cuts Gas to Ukraine
- Putin Urges Russians to Vote
- Q&A: the Russian Presidential Election
- Russia Shuts University That Displeased Putin
- EU Gas Supplies at Risk If Ukraine Does Not Settle Bill With Russia
- Monitors to Boycott Russian Election in Row Over Restrictions
- Catherine The Great - Empress of Russia
- Russia Chechnya Conflict
- Russian Babies Have Their Mouths Taped Shut by Yekaterinburg Hospital Staff
- Iran Stops Cooperating with IAEA, Still Negotiating with Russia



